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Abstract
Background: Intestinal barrier dysfunction is not only the consequence of liver cirrhosis, but also an active participant
in the development of liver cirrhosis. Previous studies showed that external administration of insulin-like growth factor
1 (IGF-1) improved intestinal barrier function in liver cirrhosis. However, the mechanism of IGF-1 on intestinal
barrier in liver cirrhosis is not fully elucidated. The present study aims to investigate the mechanisms of IGF-1
improving intestinal barrier function via regulating tight junctions in intestines.
Methods: We used carbon tetrachloride induced liver cirrhotic rats to investigate the effect of IGF-1 on intestinal
claudin-1 and occludin expressions, serum alanine transaminase (ALT) and aspartate transaminase (AST) levels,
severity of liver fibrosis, portal pressures, enterocytic apoptosis and lipopolysaccharides (LPS) levels in portal vein.
The changes of IGF-1 in serum during the development of rat liver cirrhosis were also evaluated. Additionally, we
assessed the effect of IGF-1 on claudin-1 and occludin expressions, changes of transepithelial electrical resistance
(TEER) and apoptosis in Caco-2 cells to confirm in vivo findings.
Results: Serum IGF-1 levels were decreased in the development of rat liver cirrhosis, and external administration of
IGF-1 restored serum IGF-1 levels. External administration of IGF-1 reduced serum ALT and AST levels, severity of liver
fibrosis, LPS levels in portal vein, enterocytic apoptosis and portal pressure in cirrhotic rats. External administration of
IGF-1 increased the expressions of claudin-1 and occludin in enterocytes, and attenuated tight junction dysfunction in
intestines of cirrhotic rats. LPS decreased TEER in Caco-2 cell monolayer. LPS also decreased claudin-1 and occludin
expressions and increased apoptosis in Caco-2 cells. Furthermore, IGF-1 attenuated the effect of LPS on TEER, claudin-1
expression, occludin expression and apoptosis in Caco-2 cells.
Conclusions: Tight junction dysfunction develops during the development of liver cirrhosis, and endotoxemia will
develop subsequently. Correspondingly, increased endotoxin in portal system worsens tight junction dysfunction
via decreasing intestinal occludin and claudin-1 expressions and increasing enterocytic apoptosis. Endotoxemia
and intestinal barrier dysfunction form a vicious circle. External administration of IGF-1 breaks this vicious circle.
Improvement of tight junctions might be one possible mechanism of the restoration of intestinal barrier function
mediated by IGF-1.
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Background
Decompensated liver cirrhosis is the end stage of various
chronic liver diseases with different etiologies. Complica-
tions encompassing variceal bleeding, spontaneous bac-
terial peritonitis, hepatic encephalopathy, hepatorenal
syndrome and hepatic pulmonary syndrome are com-
mon presentations of decompensated liver cirrhosis and
often life threatening to liver cirrhotic patients. All the
complications are the consequences of liver dysfunction
and portal hypertension. Intestinal barrier dysfunction is
also the consequence of portal hypertension and a risk
factor for spontaneous bacterial peritonitis. In recent
years, it is found that intestinal barrier interruption is
not only the consequence of liver cirrhosis, but also an
active participant in the development of liver damage
and portal hypertension [1, 2]. Bacterial translocation
and increased lipopolysaccharides (LPS) permeability
through defective intestinal barrier could cause pro-
inflammatory cytokines to be released from poly-
morphonuclear cells in the portal vein system. Pro-
inflammatory cytokines induce nitric oxide synthase
(NOS) overexpression and nitric oxide overproduction
in the portal vein system, which could cause hyperdy-
namic circulatory state of the portal vein system, and
portal hypertension will ensue subsequently [1, 2].
Moreover, pro-inflammatory cytokines could cause
hepatocytic injury and worsen liver dysfunction in liver
cirrhosis [3].
Insulin-like growth factor 1 (IGF-1) is a polypeptide
with an insulin like structure, and whose receptors are
widely distributed in muscles, bones, intestines, testicles
and livers [4, 5]. Apart from the pro-growth and trophic
effects of IGF-1 on various tissues, IGF-1 could act on
intestines to regulate intestinal barrier function [6]. A
previous study showed that IGF-1 reduced intestinal
barrier permeability through increasing cyclooxygenase-
2 (COX-2) expression and decreasing tumor necrosis-
alpha (TNF-alpha) expression of intestinal cells [6]. The
cytoprotective effect of prostaglandins produced by
COX-2 might be one of the mechanisms of IGF-1 im-
proving intestinal barrier function in liver cirrhosis [6].
Some previous studies also indicated that IGF-I
upregualted tight junction protein expressions in osteo-
blast- like MC3T3-E1 cells and reduced apoptosis in
mesenchymal stem cells [7, 8]. However, whether IGF-I
could regulate enterocytic tight junction proteins and
apoptosis to improve intestinal barrier functions is not
clear. In the present study, we used carbon tetrachlor-
ide (CCL4) induced liver cirrhotic rats as the animal
models to investigate the effect of IGF-1 on endotoxin
levels in portal vein, enterocytic apoptosis and portal
pressure. The effect of IGF-1 on claudin-1 and occludin
expressions in intestines was also evaluated. We also
used Caco-2 cells to confirm the effect of IGF-1 on
claudin-1 and occludin expressions in vitro. Transe-
pithelial electrical resistance was employed to evaluate
the effect of IGF-1 on cellular monolayer permeability.
Furthermore, we also evaluated the effect of IGF-1 on
LPS induced apoptosis of enterocytes. Our findings
confirmed that IGF-1 was able to decrease portal hyper-
tension by reducing portal vein endotoxin via regulating
intestinal tight junction proteins. Our findings also
enriched our knowledge about the mechanism of IGF-1
on intestinal barrier and indicated IGF-1 to be a promising
therapy for preventing bacterial translocation, reducing
hepatocytic damages and attenuating portal hypertension.
Methods
Animals
Male Sprague–Dawley rats were obtained from the Ani-
mal Center of Dalian Medical University (Dalian, China)
and kept under standard laboratory conditions. Rats
were acclimatized to the laboratory conditions for one
week before further experiments. This study was carried
out in strict accordance with the International Council for
Laboratory Animal Science. All animal experiments were
conducted in accordance with protocols approved by the
Experimental Animal Ethical Committee of Dalian Med-
ical University.
Animal model and experimental design
Thirty male rats (6-week-old) were randomly divided
into three groups (ten rats in each group) with the ran-
dom number. The liver cirrhotic group was injected with
CCL4 (0.2 ml/kg/d) intraperitoneally for 6 weeks. The
control group was administered with sterile normal sa-
line (0.2 ml/kg/d) intraperitoneally for 6 weeks. The
IGF-1 group received CCL4 (0.2 ml/kg/d) intraperitone-
ally for 6 weeks and was administered with recombinant
human IGF-1 (0.2 μg/kg/d) subcutaneously for 21 days
afterwards. All animals were scarified subsequently.
Liver, intestines and blood in portal veins and abdominal
aortas were harvested for further analyses.
Cell line and cell culture
The human colorectal adenocarcinoma cell line Caco-2
was purchased from the Chinese Academy of Medical
Sciences. Caco-2 cells were cultured in high glucose
DMEM (Gibco, Bethesda, MD, USA) supplemented with
10 % fetal bovine serum (Gibco, Bethesda, MD, USA),
1 % nonessential amino acids (Gibco, Bethesda, MD,
USA) and 1 % Glutamine (Gibco, Bethesda, MD, USA)
at 37 °C with an atmosphere of 5 % CO2.
Cell experimental design
Caco-2 cells at the logarithmic phase were collected and
incubated in a 6-well plate (5 × 105 cells per well) with
serum-free DMEM for 24 h. After attachment to the
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wall, Caco-2 cells were administered with IGF-1
(PeproTech, Rocky Hill, NJ, USA) (100 ng/ml), LPS
(Sigma-Aldrich Company, St. Louis, MO, USA) (10 μg/
ml), IGF-1 (100 ng/ml) plus LPS (10 μg/ml) and no treat-
ment for 24 h respectively. The final volume of each well
was 1 ml and each group was replicated with 6 wells.
Serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) analysis
Blood samples without anticoagulant from the abdom-
inal aorta were centrifuged at 3,000 rpm for 15 min to
collect the serum. The serum ALT and AST levels were
determined with the assay kit (Nanjing Jiancheng Bio-
engineering Institute, Nanjing, China) according to the
manufacturer’s protocols.
Hemodynamic studies of portal pressure
Rats were anaesthetized with chloral hydrate. Catheters
were inserted into the portal vein of rats and the intravas-
cular pressure was detected with the pressure transducers
(BL-420 F biological experimental system, Chengdu Tech-
nology & Market Co. Ltd., China).
Plasma endotoxin analysis
Fresh blood was collected from the portal vein of rats and
anticoagulated with heparin. Subsequently, the blood was
centrifuged at 3,000 rpm for 15 min to collect plasma.
Limulus Amebocyte Lysate test kit (Xiamen Huoshiji Cor.
Ltd., Xiamen, China) was employed to determine endo-
toxin concentration according to the manufacturer’s pro-
tocols. Briefly, the control standard endotoxin was diluted
to 0.01EU/ml, 0.025EU/ml, 0.05EU/ml and 0.1EU/ml in
pyrogen free tubes respectively. Afterwards, 100 μl diluted
endotoxin was mixed with 100 μl Limulus amoebocyte
lysate in the pyrogen free tube and heated at a
temperature of 37 °C in a water bath for sixty minutes.
The mixed sample was mixed again with 100 μl chromo-
genic substrate and heated at a temperature of 37 °C in a
water bath for another sixty minutes. Azo reagent NO.1,
Azo reagent NO.2 and Azo reagent NO.3 were added to
the reaction system successively to terminate reactions.
Five minutes later, the absorbance at 545 nm of the final
mixed sample was measured. The standard curve was
depicted with the absorbance as the x-axis and the con-
centration as the y-axis. Absorbance of the tested plasma
endotoxin was measured with the same method and the
concentration of plasma endotoxin was calculated from
the standard curve. All of the above procedures were con-
ducted in sterile conditions.
Liver histopathology and evaluation of the severity of
liver fibrosis
Fresh liver tissues were fixed in 10 % neutral formalin for
24 h before being embedded in paraffin. After embedded
in paraffin, the tissues were cut into sections with a thick-
ness of 5 μm and mounted onto slides. Masson trichrome
staining were performed according to standard proce-
dures. Image pro plus software 6.0 was used to evaluate
the severity of liver fibrosis. The percentage of fibrosis area
in the whole liver area was calculated with five visual fields
in one tissue section (×100), and the mean percentage of
fibrosis of the five visual fields stood for fibrosis severity.
Measurement of IGF-1 by Enzyme-linked immunosorbent
assay (ELISA)
The levels of serum IGF-1 were measured with the ELISA
kits (Beijing Puerweiye Biological Technology Co., Ltd.,
Beijing, China) according to the manufacture’s protocols.
Briefly, the standard IGF-1 solution was diluted to 100 ng/
ml, 50 ng/ml, 25 ng/ml, 12.5 ng/ml, 6.25 ng/ml, 3.12 ng/
ml and 1.56 ng/ml in tubes respectively. The ELISA
method was used to determine the absorbance at 450 nm
of each diluted IGF-1 solution. And the standard curve
was depicted with the absorbance as the x-axis and the
concentration as the y-axis. The absorbance of serum
IGF-1 was determined with the same ELISA method and
the concentration of serum IGF-1 was calculated from the
standard curve.
Apoptosis assay
Caco-2 cells in monolayer were fixed with 4 % paraformal-
dehyde, permeabilized with 0.2 % Triton X-100, and
blocked with skim milk prior to TUNUEL assay. We used
the In situ Cell Death Detection Kit (Roche, Indianapolis,
IN, USA) to conduct TUNEL assay according to the man-
ufacturer’s instructions. Fluorescent images were detected
with the Leica TCS NT spectral confocal imaging system
combined with the Leica DM IRBE inverted microscope
(Leica, Solms, Germany).
Transepithelial Electrical Resistance (TEER) measurement
Caco-2 cells with different treatments were seeded on
polycarbonate 12-well Transwell filter inserts (Corning
Costar Corp., Cambri dge, MA, USA; pore size 0.4 μm,
growth area 1.12 cm2) with 2 × 105 cells per well. Before
TEER measurement, Caco-2 cells on each well were
grown for 21 days and formed a polarized monolayer.
The Millicell ERS instrument (Millipore, Bedford, MA,
USA) was used to determine the TEER values of the
Caco-2 cell monolayer. The changes of TEER were cal-
culated with the formula: TEER = (R1-R0) × A (Ω · cm2).
R1 and R0 represented the TEER values of the cell
monolayer wells and the background wells without cells
respectively, and A (cm2) represented the surface area of
cell monolayer on the insert.
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Western blot analysis
The resected terminal ileum tissues were mixed with the
lysis buffer (1 % Triton X-100; 50 mmol/L Tris–HCl,
pH 7.6; 150 mmol/L NaCl; and 1 % protease inhibitor)
and centrifuged at 12,000 r/min for 5 min at 4 °C. The
supernatant was separated and collected. Caco-2 cells
were harvested, washed with the cold PBS (PH 7.4) and
mixed with the lysis buffer. The total proteins of tissues
and Caco-2 cells were exacted with the protein extraction
kit (Nanjing KeyGEN Biotech Co. Ltd., Nanjing, China)
following the manufacturer’s instructions. The protein
concentration was determined with the bicinchoninic acid
(BCA) protein assay. After separated with SDS-PAGE, the
proteins were transferred to a PVDF membrane. The
PVDF membrane was block with 5 % skim milk in Tris-
buffered saline containing 0.05 % Tween-20 (TTBS), incu-
bated with the primary antibodies (occludin antibody
(Santa Cruz, CA, USA, 1:1000 dilution), claudin-1 anti-
body (Abcam, Cambridge, MA, USA, 1:1000 dilution) and
beta-actin antibody (Zhongshan Goldenbridge Biological
Technology, Beijing, China, 1:1000 dilution)) overnight at
4 °C and subsequently incubated with the secondary anti-
body for 2 h at 37 °C. The bands were photographed and
quantified with the ChemiDoc XRS documentation sys-
tem (Bio-Rad Laboratories). The intensity of the beta-
actin band was as the internal reference.
Reverse transcription-polymerase chain reactions
(RT-PCRs) analysis
Total RNA was extracted from the tissues and Caco-2
cells with TRIZOL reagent (Keygen Biotech Co., Ltd, Nan-
jing, China). We measured the optical density of the prod-
ucts at 260 nm (A260 = 1 for 40 μg/mL RNA) to quantify
RNA, and calculated the ratio of the optical density ob-
tained at 260 and 280 nm (pure RNA: A260/A280 = 2.0)
to determine the purity of RNA. All the optical analyses
were conducted with the UV-1206 spectrophotometer
(Shimadzu, Japan). Reverse transcription PCR was per-
formed with a Takara RNA PCR Kit (Takara bio inc., Da-
lian, China). The primers were listed in Table 1. PCR
conditions were as the followings: denaturation at 95 °C
for 30 s, followed by 40 cycles of denaturation at 95 °C for
5 s, 30 s at 60 °C for annealing and 30 s at 72 °C for elong-
ation. PCR products were separated by 1.5 % agarose gel
electrophoresis subsequently. The product bands were
photographed. The density of each band was quantified
and adjusted with the internal reference beta-actin.
Statistical analysis
Data are expressed as mean and standard deviation
(SD). One-way ANOVA analysis and least significant dif-
ference (LSD) test were employed to determine the dif-
ference of means among different groups. P <0.05 was
considered statistically significant. All statistical analyses
were performed with the SPSS16.0 statistical software
package (SPSS Inc., Chicago, IL, USA).
Results
IGF-1 attenuates liver cirrhosis
After 6 weeks of CCL4 administration, rats developed
liver cirrhosis with ascites. Liver cirrhosis was confirmed
with liver histology (Fig. 1b and c). Serum ALT and AST
levels of liver cirrhosis rats were higher than those of the
control rats (Fig. 2a and b), which indicated enhanced
hepatocelluar damages in liver cirrhotic rats. Moreover,
the IGF-1 level of liver cirrhosis group was reduced
compared with that of the control group (Fig. 2c), which
indicated IGF-1 insufficiency in liver cirrhosis. External
administration of IGF-1 restored IGF-1 level of liver cir-
rhosis and reduced the levels of serum ALT and AST
(Fig. 2a, b and c), which implicated that IGF-1 protected
hepatocytes from damaging in liver cirrhosis. Liver fibro-
sis severity analysis showed that external administration
of IGF-1 attenuated liver fibrosis (Fig. 1a, b and c).
IGF-1 reduces the levels of plasma endotoxin via
regulating intestinal tight junctions and subsequently
reduces portal hypertension
Endotoxin was previously proven to be a precipitating
factor in the development of cirrhotic portal hypertension.
Table 1 The primers of BCL-2, Bax, claudin-1 and occludin of
humans and rats
Gene Forward/Reverse Sequence 5′-3′
Rat BCL-2 Forward AAACGTCCAGAGTGCTAC
Reverse CAGCCAGATTTAGGTTCA
Human BCL-2 Forward GAAGCATACCCGTTTAGC
Reverse CGAGAACTGGGAGAAGAA
Rat Bax Forward GGCGATGAACTGGACAAC
Reverse GTGAGTGAGGCAGTGAGGA
Human Bax Forward CTGACGGCAACTTCAACTG
Reverse GAAAACGCATTATAGACCACA
Rat claudin-1 Forward GTGGATGTCCTGCGTTTC
Reverse GTGTTGGGTAAGAGGTTGTT
Human claudin-1 Forward CTTCATTCTCGCCTTCCT
Reverse TGACAGCCATCCTCATCTT
Rat occludin Forward AACCCGAAGAAAGATGGA
Reverse TCTGAAGTGATAGGTGGATA
Human occludin Forward TATGCCCTCTGCAACCAA
Reverse CACCGCTGCTGTAACGAG
Rat beta-actin Forward GAGGGAAATCGTGCGTGAC
Reverse CTGGAAGGTGGACAGTGAG
Human beta-actin Forward GGAGATTACTGCCCTGGCTCCTA
Reverse GACTCATCGTACTCCTGCTTGCTG
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We postulated that IGF-1 could strengthen intestinal
junctions and prevent gut endotoxin from entering portal
vein system. Through reducing plasma endotoxin level,
IGF-1 could reduce portal hypertension. As expected, por-
tal pressure of the liver cirrhosis group was higher than
that of the control group significantly, and external ad-
ministration of IGF-1 reduced portal pressure of the liver
cirrhotic rats (Fig. 3a), which showed that IGF-1 was a
negative regulating factor in portal hypertension of liver
cirrhosis. Not surprisingly, plasma endotoxin entering
portal veins were increased during the development of
liver cirrhosis (Fig. 3b), and this effect was via decreased
expressions of occludin and claudin-1 in intestines (Fig. 4a,
b, c and d),which indicated tight junction dysfunction
playing important roles in endotoxemia development of
liver cirrhosis. Moreover, external administration of IGF-1
reduced plasma endotoxin levels in portal veins of liver
cirrhotic rats (Fig. 3b), and this effect was via increased ex-
pressions of occludin and claudin-1 in intestines (Fig. 4a,
b, c and d). So IGF-1 improved intestinal tight junction
function via upregulating occludin and claudin-1 expres-
sions. With improvement of intestinal tight junction
function, endotoxemia would be alleviated. We also used
in vitro experiments to confirm our in vivo findings. As
expected, LPS reduced the TEER values in Caco-2 cell
monolayer (Fig. 3c). Furthermore, we found that IGF-1 in-
creased the TEER values (Fig. 3c) in Caco-2 monolayer
through upregulating occludin and caludin-1 expressions
(Fig. 4e, f, g and h), which indicated that IGF-1 upregu-
lated these two tight junction proteins in intestinal cells to
restore intestinal tight junctions. With this cell experi-
ment, LPS was also proven to be able to cause tight junc-
tion dysfunction. Endotoxemia and intestinal barrier
dysfunction forms a vicious circle.
IGF-1 inhibits enterocytic apoptosis in vivo and in vitro
We also postulated that high endotoxin levels in portal
veins increased enterocytic apoptosis, and increased
enterocytic apoptosis caused intestinal tight junction
damages subsequently. TUNEL assay was used to evalu-
ate apoptosis in vitro and in vivo. As expected, apoptosis
of enterocytes was increased during the development of
liver cirrhosis (Fig. 5a and b) via regulating Bax and Bcl-
2 (Fig. 6a and b), and external administration of IGF-1
Fig. 1 a Administration of IGF-1 reduced the severity of fibrosis in liver cirrhosis rats. b Representative histology of the cirrhosis without IGF-1
group. c Representative histology of the IGF-1 treated cirrhosis group. Data were shown with the mean ± SD. *P <0.01 vs. CCL4 group
Fig. 2 a and b The levels of serum ALT and AST were increased in liver cirrhosis rats, and administration of IGF-1 reduced the levels of serum ALT
and AST in liver cirrhosis rats. c IGF-1 was decreased in the development of liver cirrhosis, and administration of IGF-1 restored the levels of IGF-1
in liver cirrhosis rats. Data were shown with the mean ± SD. **P <0.001 vs. control group, ## P <0.001 vs. CCL4 group
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reduced enterocytic apoptosis in liver cirrhotic rats
(Fig. 5b and c) through regulating Bax and Bcl-2 (Fig. 6a
and b). In vitro experiment with Caco-2 cells proved that
LPS promoted apoptosis via Bax and Bcl-2, and IGF-1
attenuated the LPS induced apoptosis through regulating
Bax and Bcl-2 (Fig. 6c and d). So IGF-1 improved intes-
tinal barrier function through attenuating apoptosis of
enterocytes.
Discussion
Intestinal barrier dysfunction causing bacterial transloca-
tion and endotoxemia is the consequence of decompen-
sated liver cirrhosis. Bacterial translocation is a risk
factor for spontaneous bacterial peritonitis, which in-
creases mortality of the liver cirrhosis patients conse-
quently. Moreover, endotoxemia causes pro-inflammatory
cytokines to be released from polymorphonuclear cells in
Fig. 3 a Portal pressure of the liver cirrhosis group was higher than that of the control group significantly, and external administration of IGF-1 reduced
portal pressure of the liver cirrhosis. b Plasma endotoxin levels of the liver cirrhosis group were higher than those of the control group significantly,
and external administration of IGF-1 reduced plasma endotoxin levels of the liver cirrhosis. c TEER values of Caco-2 cell monolayer in LPS group were
lower than those of Caco-2 cell monolayer in the control group. IGF-1 increased the TEER values of Caco-2 monolayer as compared with those of the
LPS group. Data were shown with the mean ± SD. **P <0.001 vs. control group, ## P <0.001 vs. CCL4 group or LPS group
Fig. 4 a and b occludin level in intestines was decreased during the development of liver cirrhosis in rats, and administration of IGF-1 restored
occludin level in intestines in liver cirrhosis to some extent. c and d claudin-1 level in intestines was decreased during the development of liver
cirrhosis in rats, and administration of IGF-1 restored claudin-1 level in intestines in liver cirrhosis to some extent. e and f Administration of LPS to
Caco-2 cells reduced occludin level, and external administration of IGF-1 attenuated the effect of LPS on occludin expression in Caco-2 cells. g
and h Administration of LPS to Caco-2 cells reduced claudin-1 level, and external administration of IGF-1 attenuated the effect of LPS on claudin-1
expression in Caco-2 cells. Data were shown with the mean ± SD. **P <0.001 vs. control group, ## P <0.001 vs. CCL4 group or LPS group
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the portal vein system. The released pro-inflammatory cy-
tokines worsens portal hypertension and liver damages
[3]. Additionally, pro-inflammatory cytokines in portal
vein system also attacks intestinal epithelia and aggravates
intestinal barrier dysfunction. Therefore, intestinal barrier
dysfunction per se is also an active participant in liver cir-
rhosis not just a passive victim.
Intestinal barrier consists of microorganism barrier,
mucus adhering to the apical surface of enterocytes,
tight junction complexes sealing adjacent enterocytes,
abundant intestinal epithelia, immune barrier (primary
immune system and secondary immune system) and the
enteric nervous system [9, 10]. Among these intestinal
barrier components, abundant intestinal epithelia and
tight junctions sealing adjacent intestinal endothelia are
the fundamental architectures. Furthermore, abundant
intestinal epithelia provide the anchor points to tight
junctions and are integral parts of tight junctions. Two
epidemiological studies showed intestinal tight junction
proteins down-regulated in decompensated liver cirrho-
sis patients as compared with compensated ones and
healthy controls [11, 12]. Additionally, this two excellent
case control studies indicated occludin, claudin-1 and
claudin-2 as the significant altered tight junction pro-
teins during the liver cirrhosis decompensating process
[11, 12]. Our animal experiment indicated that occludin
and claudin-1 decreased during liver cirrhosis develop-
ment, endotoxin in portal system was also found ele-
vated due to the tight junction dysfunction in liver
cirrhotic rats. These results are in consistence with the
findings of the previous epidemiological studies [11, 12].
Furthermore, we also found that intestinal apoptosis was
increased in liver cirrhtic rats. Abundant intestinal epithe-
lia are the fundamental architectures for intestinal barrier
and the attachment points of tight junction complexes, in-
creased intestinal apoptosis would cause intestinal tight
junction dysfunction in liver cirrhosis subsequently.
Endotoxemia caused by intestinal barrier dysfunction
is an active participant in intestinal barrier dysfunction.
Previous studies revealed that LPS challenged rats
showed increased intestinal permeability and decreased
intestinal occludin expression [13, 14]. Our results sup-
port endotoxin playing important roles in intestinal tight
junction dysfunction. Through cell experiment, we found
that LPS reduced the TEER values in Caco-2 cell mono-
layer. Moreover, the effect of LPS on the permeability of
Caco-2 cell monolayer is via down-regulating occludin
and claudin-1. Increased LPS permeability through defect-
ive intestinal barrier could cause pro-inflammatory cyto-
kines to be released from polymorphonuclear cells in the
portal vein system. Pro-inflammatory cytokines induce
NOS overexpression and nitric oxide overproduction in
Fig. 5 Apoptosis of intestinal cells in rats was increased during the development of liver cirrhosis, and external administration of IGF-1 reduced
intestinal cell apoptosis in liver cirrhosis rats: a Control group, b CCL4 group, c CCL4 + IGF-1 group. LPS induced Caco-2 cell apoptosis and IGF-1
inhibited LPS induced Caco-2 cell apoptosis: d Control group, e IGF-1 group, f LPS group, (G) LPS + IGF-1 group
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the portal vein system, which could cause hyperdynamic
circulatory state of the portal vein system and portal
hypertension [1, 2, 12]. Additionally, LPS activates Kupffer
cells secreting vasoconstrictors such as thromboxane A2
and cysteinyl leukotrienes, which increase intrahepatic re-
sistance and promote portal hypertension development
[15, 16]. Taken together, endotoxemia and intestinal bar-
rier dysfunction (especially intestinal tight junction dys-
function) very likely form a vicious circle [11], breaking
this vicious circle may have great clinical significance to
liver cirrhosis patients.
IGF-I is a polypeptide with an insulin like structure,
whose receptor is also distributed in intestines [4, 5]. IGF-
1 is reduced in liver cirrhosis patients, and negatively
correlated with MELD score and liver cirrhosis severity
[17–19]. As liver is the major synthesis site for IGF-1 and
growth hormone (GH) receptor, reduced IGF-1 in liver
cirrhosis could be explained by reduced liver function for
synthesizing IGF-1 and impaired GH response in liver
[19–23]. Moreover, LPS penetrating defect intestinal bar-
rier in liver cirrhosis could also reduce GH releasing in
pituitory, IGF-1 synthesis and release in liver would be re-
duced consequently [24–26]. IGF-I has trophic effects on
intestinal epithelia, so IGF-1 deficiency could cause intes-
tinal barrier dysfunction. A previous study showed that
IGF-1 reduced intestinal barrier permeability through in-
creasing COX-2 expression and decreasing TNF-alpha ex-
pression of enterocytes [6]. The cytoprotective effect of
Fig. 6 a and b Bax was increased and Bcl-2 was decreased in intestines during the development of liver cirrhosis in rats, and administration of
IGF-1 attenuated Bax and Bcl-2 changes in intestines of liver cirrhosis rats. c and d Administration of LPS to Caco-2 cells decreased Bax level and
increased Bcl-2 level, and IGF-1 attenuated the effect of LPS on Bax and Bcl-2 expressions in Caco-2 cells. Data were shown with the mean ± SD.
**P <0.001 vs. control group, ## P <0.001 vs. CCL4 group or LPS group
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prostaglandin produced by COX-2 might be one of the
mechanisms of IGF-1 improving intestinal barrier func-
tion in liver cirrhosis [6]. However, whether IGF-I could
regulate tight junction to improve intestinal barrier is not
clear. So we evaluated the effect of IGF-1 on tight junction
in vivo and in vitro. Our animal experiment showed that
external administration of IGF-1 reduced endotoxemia in
liver cirrhotic rats via up-regulating occludin and claudin-
1 expression in intestines. Additionally, external adminis-
tration of IGF-1 also attenuated enterocytic apoptosis,
which ensured abundant tight junction attaching points.
Through these mechanisms, intestinal tight junction func-
tion would be improved. Cell experiment confirmed our
findings in animal experiment. As shown above in the
results section, IGF-1 countered the effect of LPS on in-
testinal tight junction protein expression and apoptosis.
IGF-1 is able to break the vicious circle of endotoxemia
and intestinal barrier dysfunction.
Previous studies also indicated IGF-1 having the ability
of anti-fibrosis. Gene transfer of IGF-1 to the hepatic tis-
sues is proven to be able to improve liver histology and
functions in established liver cirrhotic rats [27]. Our data
confirm that external administration of IGF-1 can re-
duce hepatocellular injury and attenuate liver cirrhosis,
which is consistent with that of the previous studies [28,
29]. Our explanation is that IGF-1 reduces portal LPS
level through improving intestinal barrier function, re-
duced LPS alleviates hepatic stellate cells (HSC) activa-
tion which is a key player in the development of liver
cirrhosis [30, 31]. The trophic effect of IGF-1 on hepato-
cytes also possibly contributes to the improvement of
liver cirrhosis. However, the panorama of the mechan-
ism of IGF-1 alleviating liver fibrosis still needs to be
elucidated.
Conclusions
In summary, tight junction dysfunction develops during
the development of liver cirrhosis, and endotoxemia will
ensue subsequently. Correspondingly, increased endo-
toxin in portal system worsens tight junction dysfunc-
tion via decreasing intestinal occludin and claudin-1
expressions and increasing enterocytic apoptosis. Endo-
toxemia and intestinal barrier dysfunction form a vicious
circle. External administration of IGF-1 breaks this vi-
cious circle. Improvement of tight junctions might be
one possible mechanism of the restoration of intestinal
barrier function mediated by IGF-1. Moreover, improved
intestinal barrier by IGF-1 reduces portal LPS and atten-
uates Kuppfer cell and HSC activations. Decreased in-
flammation, reduced HSC activation and the trophic
effect of IGF-1 on hepatocytes attenuates liver cirrhosis.
Our data further supports IGF-1 as a potential therapy
for liver cirrhosis and enriches our knowledge about
IGF-1 on intestinal barrier dysfunction.
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